Antimicrobial dosing in special populations

Renal Impairment - Kidney-Friendly Dosing

• Principle: Prevent drug toxicity for agents cleared by the kidneys. Adjust dose, extend interval, or both.

• Action: Calculate Creatinine Clearance (CrCl) to estimate Glomerular Filtration Rate (GFR).

  • Formula (Cockcroft-Gault): $CrCl = \frac{(140 - Age) \times Weight (kg)}{72 \times SCr (mg/dL)} \times (0.85 \text{ if female})$

• Commonly Requiring Adjustment:

  • Penicillins (except nafcillin/oxacillin)
  • Cephalosporins (except ceftriaxone)
  • Vancomycin, Aminoglycosides (e.g., Gentamicin)
  • Fluoroquinolones (except moxifloxacin)

⭐ Exam Favorite: Several antimicrobials are hepatically cleared and do not require renal dose adjustments. Key examples include Ceftriaxone, Doxycycline, Azithromycin, Clindamycin, and Metronidazole.

Hepatic Impairment - Liver-Safe Choices

• Guiding principle: Select antimicrobials with minimal hepatic metabolism and low intrinsic hepatotoxicity. While the Child-Pugh score offers a general guide, drug-specific recommendations are paramount.

• Generally Safe Agents (Primarily Renal Excretion):

  • Penicillins: Most are well-tolerated (e.g., Piperacillin-Tazobactam).
  • Cephalosporins: Most generations are safe.
    • Caution: Ceftriaxone (significant biliary excretion).
  • Aminoglycosides: Gentamicin, Tobramycin.
  • Vancomycin.
  • Fluoroquinolones: Ciprofloxacin, Levofloxacin.
  • Carbapenems: Meropenem, Ertapenem.

⭐ Amoxicillin-clavulanate is a notorious cause of drug-induced liver injury (DILI). The injury pattern is typically cholestatic hepatitis, which can manifest weeks after the course is completed and is linked to the clavulanate component.

Obesity Dosing - Weighty Matters

Obesity alters drug pharmacokinetics, particularly the volume of distribution (Vd). Dosing adjustments are critical to ensure efficacy and avoid toxicity.

• Dosing Weight Strategy:

-   Use Adjusted Body Weight (AdjBW) for many hydrophilic drugs.
-   $AdjBW = IBW + 0.4 * (TBW - IBW)$

⭐ High-Yield: Aminoglycosides dosed on Total Body Weight (TBW) in obese patients can lead to supratherapeutic levels and ↑ risk of nephrotoxicity and ototoxicity. Always use an adjusted or ideal body weight for them.

Other Populations - Cradle to Grave

• Pediatrics (Neonate/Infant):

  • Dosing is weight-based (mg/kg).
  • Immature renal/hepatic function → ↓ clearance, ↑ half-life.
  • Avoid: Tetracyclines (bone/teeth), Fluoroquinolones (cartilage), Ceftriaxone & Sulfonamides (kernicterus risk).

• Geriatrics:

  • ↓ Renal clearance is primary concern; adjust dose for CrCl.
  • Altered body composition (↑ fat, ↓ water) affects volume of distribution.
  • High risk of drug interactions from polypharmacy.

• Pregnancy:

  • Physiologic ↑ in GFR & volume of distribution may require dose increases.
  • Most drugs cross the placenta.
  • Safe: Penicillins, Cephalosporins.
  • Avoid: Tetracyclines, Fluoroquinolones.

⭐ Chloramphenicol in neonates can cause "Gray Baby Syndrome" (cardiovascular collapse) due to deficient glucuronidation.

High‑Yield Points - ⚡ Biggest Takeaways

• Renal failure requires dose reduction for drugs like vancomycin and aminoglycosides.
• Hepatic dysfunction affects liver-metabolized agents like metronidazole and macrolides.
• In obesity, lipophilic drugs (e.g., fluoroquinolones) may need higher, weight-based doses.
• Pregnancy alters pharmacokinetics; avoid teratogens like tetracyclines and fluoroquinolones.
• Neonates and the elderly have reduced clearance, mandating careful dose adjustments.
• Aminoglycosides use concentration-dependent killing, allowing once-daily dosing.